313263-08-0
Chemical Structure
Geranylgeranyl pyrophosphate triammonium
- CAS No.: 313263-08-0
- Formula:C20H45N3O7P2
- Molecular Weight:501.53
IUPAC Name: (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl trihydrogen diphosphate, triammonia salt
InChIKey: DPBMYHRTNHKGIT-XGVVNRHLSA-N
SMILES: O=P(O)(OP(O)(O)=O)OC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C.N.N.N
Biological Activity: Geranylgeranyl pyrophosphate triammonium is a type of isoprenoid metabolic intermediate, mainly synthesized through the mevalonate pathway. Geranylgeranyl pyrophosphate triammonium is a key precursor in various biological synthesis processes, especially as a necessary substrate for post-translational modification of proteins - geranylgeranyl phosphorylation. Geranylgeranyl pyrophosphate triammonium regulates various cellular processes and disease progression through protein geranylgeranyl phosphorylation, such as activating the YAP signaling pathway, promoting cell proliferation and inhibiting apoptosis; promoting IL-2 production and STAT5 phosphorylation; and influencing metabolic homeostasis and cancer, etc[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Geranylgeranyl pyrophosphate triammonium | 95.0% | Geranylgeranyl pyrophosphate triammonium is a type of isoprenoid metabolic intermediate, mainly synthesized through the mevalonate pathway. Geranylgeranyl pyrophosphate triammonium is a key precursor in various biological synthesis processes, especially as a necessary substrate for post-translational modification of proteins - geranylgeranyl phosphorylation. Geranylgeranyl pyrophosphate triammonium regulates various cellular processes and disease progression through protein geranylgeranyl phosphorylation, such as activating the YAP signaling pathway, promoting cell proliferation and inhibiting apoptosis; promoting IL-2 production and STAT5 phosphorylation; and influencing metabolic homeostasis and cancer, etc. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhu L, et al. Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension. Circulation. 2021 May 4;143(18):1775-1792. [Content Brief]
- [2]. Wang L, et al. Geranylgeranyl pyrophosphate depletion by statins compromises skeletal muscle insulin sensitivity. J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2697-2711. [Content Brief]
- [3]. Ross GR, et al. Geranylgeranyl Pyrophosphate Promotes Profibrotic Factors and Collagen-Specific Chaperone HSP47 in Fibroblasts. J Cell Mol Med. 2024 Dec;28(24):e70273. [Content Brief]
- [4]. Zhao Y, et al. Geranylgeranyl Pyrophosphate Promotes Hepatic Lipid Accumulation by Prenylation of Perilipin4. Cell Mol Gastroenterol Hepatol. 2025;19(9):101546. [Content Brief]
- [5]. Pandit M, et al. Geranylgeranyl pyrophosphate amplifies Treg differentiation via increased IL-2 expression to ameliorate DSS-induced colitis. Eur J Immunol. 2021 Jun;51(6):1461-1472. [Content Brief]
- [6]. Waller DD, et al. Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. Crit Rev Biochem Mol Biol. 2019 Feb;54(1):41-60. [Content Brief]
